5%+ major-holding disclosures
- 김건수29.34%2026-07-23 · 증감 +0.02%p
- 미래에셋셀트리온신성장투자조합1호5.76%2026-05-07 · 증감 -0.19%p
Curocell
372320 · KOSDAQ₩24,050+0.00%
2026-09-04 closeCurocell last closed at ₩24,050 (+0.00%) on 2026-09-04. Signals today: MACD bullish cross. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
F
Overall: 상사,자본재 74/74 · top 100%
Factor composite · relative position in sector
PER — · PBR 11.78 — own-history percentile 0/100 · —/100
Open self-history band
PER0/100
PBR—/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -14.04
Distress
Grey
Safe
- Altman Z''
- -14.04
- Beneish M-Score
- —
- Sloan accrual
- -13.63%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Key suppliers · Annual report
Annual reportDART · 2026-03-19Suppliers disclosed by the company in its 2026-03-19 annual report.
Suppliers without disclosed amount
REX
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 글로본KRA019660 →
Shared holders: 김건수
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
Same theme
CAR-T면역항암제
Recent filings
Curocell's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Curocell
- What technical signals does Curocell (372320) have?
- Curocell current technical signals: no active technical signal.
- Is Curocell a cup-and-handle pattern?
- No. Curocell has no valid cup-and-handle signal right now.
- What are Curocell's financials and valuation?
- Curocell's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy